Literature DB >> 21337603

Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-¹¹C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole.

Bruno Stankoff1, Leorah Freeman, Marie-Stéphane Aigrot, Audrey Chardain, Frédéric Dollé, Anna Williams, Damien Galanaud, Lucie Armand, Stéphane Lehericy, Catherine Lubetzki, Bernard Zalc, Michel Bottlaender.   

Abstract

OBJECTIVE: Imaging of myelin tracts in vivo would greatly improve the monitoring of demyelinating diseases such as multiple sclerosis (MS). To date, no imaging technique specifically targets demyelination and remyelination. Recently, amyloid markers related to Congo red have been shown to bind to central nervous system (CNS) myelin. Here we questioned whether the thioflavine-T derivative 2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PIB), which also binds to amyloid plaques, could serve as a myelin marker.
METHODS: PIB fixation to myelin was studied by fluorescence in the normal and dysmyelinating mouse brain, as well as in the postmortem brain of MS patients. Positron emission tomography (PET) experiments were conducted using [¹¹C]PIB in baboons and in a proof of concept clinical study in 2 MS patients.
RESULTS: Applied directly on tissue sections or after intraperitoneal injection, PIB stained CNS myelin, and the decrease in the level of fixation paralleled the amount of myelin loss in a dysmyelinating mutant. In normally myelinated areas of postmortem MS brain, demyelinated and remyelinated lesions were clearly distinguishable by the differential intensity of labeling observed with PIB. PET using intravenously injected radiolabeled [¹¹C]PIB imaged CNS myelin in baboons and humans. In MS patients, the dynamic analysis of PET acquisitions allowed quantitative assessment of demyelination.
INTERPRETATION: PIB could be used as an imaging marker to quantify myelin loss and repair in demyelinating diseases.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21337603     DOI: 10.1002/ana.22320

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  77 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

3.  Separation of β-amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis.

Authors:  Kerstin Heurling; Christopher Buckley; Rik Vandenberghe; Koen Van Laere; Mark Lubberink
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

Review 4.  Myelin architecture: zippering membranes tightly together.

Authors:  Mostafa Bakhti; Shweta Aggarwal; Mikael Simons
Journal:  Cell Mol Life Sci       Date:  2013-10-29       Impact factor: 9.261

Review 5.  Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.

Authors:  Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

6.  Reduced retention of Pittsburgh compound B in white matter lesions.

Authors:  Lidia Glodzik; Henry Rusinek; Jinyu Li; Cyrus Zhou; Wai Tsui; Lisa Mosconi; Yi Li; Ricardo Osorio; Schantel Williams; Catherine Randall; Nicole Spector; Pauline McHugh; John Murray; Elizabeth Pirraglia; Shankar Vallabhajolusa; Mony de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

7.  A new frontier for amyloid PET imaging: multiple sclerosis.

Authors:  Silvia Morbelli; Matteo Bauckneht; Selene Capitanio; Matteo Pardini; Luca Roccatagliata; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-15       Impact factor: 9.236

8.  Multimodal partial volume correction: Application to [11C]PIB PET/MRI myelin imaging in multiple sclerosis.

Authors:  Elisabetta Grecchi; Mattia Veronese; Benedetta Bodini; Daniel García-Lorenzo; Marco Battaglini; Bruno Stankoff; Federico E Turkheimer
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study.

Authors:  Denis Peruzzo; Marco Castellaro; Massimiliano Calabrese; Elisa Veronese; Francesca Rinaldi; Valentina Bernardi; Alice Favaretto; Paolo Gallo; Alessandra Bertoldo
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.